BMY Bristol Myers Squibb

XNYS Sideways Alert

Health Care

· How we analyze

About the company

Bristol Myers Squibb is a pharmaceutical company from New Jersey. Its focus areas are cancer drugs such as Opdivo, blood thinners (Eliquis, together with Pfizer), immunology and cardiovascular disease. The acquisition of Karuna added a schizophrenia treatment. As of Oct 11, 2026

Fact sheet (from the annual report) Pharmaceutical manufacturers · Princeton, USA

The company researches, develops, manufactures and markets medicines in a single segment. Its therapeutic areas are oncology, hematology, immunology, cardiovascular disease and neuroscience. Its products include Opdivo and Yervoy for several types of cancer, the anticoagulant Eliquis and Revlimid for multiple myeloma. Customers are mainly wholesalers, distributors and specialty pharmacies, and to a lesser extent also retailers, hospitals and government agencies. In the US market, Revlimid and Pomalyst are distributed mainly through contracted pharmacies with mandatory risk programs. Manufacturing sites include Puerto Rico, among others.

Automatically summarized from SEC annual report (10-K, filed Feb 11, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

Price performance at a glance

Last 30 trading days
  • Today +0.2%
  • 7 days +4.7%
  • 30 days −2.0%
  • 1 year +40.6%
Day range (last trading day)
−0.8%Price at 53% of the range+0.7%
52-week range
−31.0%Price at 73% of the range+11.4%
Distance from the all-time high
−24.3%

Our own calculation from the exchange’s daily candles, as of Oct 26, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Gap with volume · Analysis method

This method currently detects no pattern for BMY. The check runs daily after the close.

You see new patterns immediately from Watcher, on the free plan 2 days after they form. Plans and pricing

What does the pattern show?

What is this? After strong news, usually earnings, the price opened above the previous day’s high and closed much higher on heavy volume. Such moves often continue for a few more days.

This is a calculated analysis, not a forecast and not a call to buy. Risk notice and investment advice

Load chart from TradingView

This transfers data (including your IP address) to TradingView, also to the USA. More in the Privacy policy.

Symbol on TradingView: NYSE:BMY

Fundamental analysis

Bristol Myers Squibb · Sector Health Care · amounts in USD

Information only – does not affect the other analysis methods, not investment advice. Source: SEC filings, As of Feb 11, 2026.

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 31, 2025

Quality Profitability, consistency, balance sheet · 1 without data 5 of 7 criteria met Growth Revenue and earnings per share · 1 without data 2 of 6 criteria met Dividend Level, consistency, coverage 6 of 7 criteria met Financial strength Piotroski, debt, liquidity 5 of 6 criteria met

Quality 5 of 7 met · 1 without data

  • met: Gross margin above 40% 71.1%
  • no data: Operating margin above 15% not stated in the SEC filings
  • met: Net margin above 10% 14.6%
  • met: Return on equity above 15% 38.2%
  • met: Free cash flow margin above 10% 26.7%
  • not met: Profit in each of the last 5 fiscal years 4 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • not met: Equity ratio above 30% 20.5%
Gross margin

71.1% Fiscal year 2025

Rank 82 of 100: higher than 82% of 153 peers (All). strong.

Rank 68 of 100: higher than 68% of 20 peers (Sector). strong.

Median Health Care: 66.6%

Share of revenue left after the direct cost of the products sold.

Net margin

14.6% Fiscal year 2025

Rank 53 of 100: higher than 53% of 237 peers (All). medium.

Rank 52 of 100: higher than 52% of 26 peers (Sector). medium.

Median Health Care: 13.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

38.2% Fiscal year 2025

Rank 81 of 100: higher than 81% of 218 peers (All). strong.

Rank 88 of 100: higher than 88% of 21 peers (Sector). strong.

Median Health Care: 14.3%

Net income divided by equity at fiscal year end.

Return on assets

7.8% Fiscal year 2025 (total assets at year end)

Rank 62 of 100: higher than 62% of 238 peers (All). medium.

Rank 60 of 100: higher than 60% of 26 peers (Sector). medium.

Median Health Care: 6.4%

Net income divided by total assets at fiscal year end.

Equity ratio

20.5% Fiscal year 2025

Rank 25 of 100: higher than 25% of 239 peers (All). weak.

Rank 25 of 100: higher than 25% of 26 peers (Sector). weak.

Median Health Care: 38.5%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

26.7% Fiscal year 2025

Rank 79 of 100: higher than 79% of 213 peers (All). strong.

Rank 86 of 100: higher than 86% of 25 peers (Sector). strong.

Median Health Care: 14.9%

Free cash flow divided by revenue.

Free cash flow

12.8B USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 2 of 6 met · 1 without data

  • not met: Over 3 years, revenue grew by more than 5% per year +1.4%
  • not met: Over 5 years, revenue grew by more than 5% per year +2.5%
  • met: Over 10 years, revenue grew by more than 5% per year +11.3%
  • met: Over 3 years, EPS grew by more than 5% per year +5.5%
  • no data: Over 5 years, EPS grew by more than 5% per year not computable (loss in the first or last year, or figures missing)
  • not met: Revenue rose in at least 4 of the last 5 fiscal years 2 of 5
  • not met: Revenue rose in the last fiscal year −0.2%
Revenue growth 3 years

+1.4% per year

Rank 21 of 100: higher than 21% of 230 peers (All). weak.

Rank 30 of 100: higher than 30% of 25 peers (Sector). weak.

Median Health Care: +5.6%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+2.5% per year

Rank 10 of 100: higher than 10% of 217 peers (All). weak.

Rank 6 of 100: higher than 6% of 25 peers (Sector). weak.

Median Health Care: +8.5%

Average growth per year over 5 fiscal years.

Revenue growth 10 years

+11.3% per year

Rank 69 of 100: higher than 69% of 157 peers (All). strong.

Rank 66 of 100: higher than 66% of 19 peers (Sector). medium.

Median Health Care: +10.1%

Average growth per year over 10 fiscal years.

EPS growth 3 years

+5.5% per year

Rank 32 of 100: higher than 32% of 157 peers (All). weak.

Rank 48 of 100: higher than 48% of 22 peers (Sector). medium.

Median Health Care: +5.5%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 10 years

+14.0% per year

Rank 67 of 100: higher than 67% of 140 peers (All). strong.

Rank 68 of 100: higher than 68% of 20 peers (Sector). strong.

Median Health Care: +8.3%

Growth of earnings per share per year, adjusted for stock splits.

Dividend 6 of 7 met

  • met: Pays a dividend 2.49 USD
  • not met: Payout ratio at most 60% of earnings 72%
  • met: Dividend paid in each of the last 5 fiscal years 5 of 5
  • met: Dividend per share never lowered in the last 5 fiscal years Dividend per share as filed with the SEC, including special dividends; a one-off higher prior year does not count as a cut. never
  • met: Dividend per share higher than 5 years ago +6.2%
  • met: Free cash flow per share covers the dividend 2.5x
  • met: Dividends paid over the last 5 years covered by free cash flow 36% of free cash flow
Payout ratio

72% Fiscal year 2025

Dividend per share divided by earnings per share.

Dividend growth 5 years

+6.2% per year

Rank 29 of 100: higher than 29% of 118 peers (All). weak.

Rank 34 of 100: higher than 34% of 16 peers (Sector). medium.

Median Health Care: +7.8%

Growth of the dividend per share per year.

Free cash flow coverage

2.5x Fiscal year 2025

Free cash flow per share divided by dividend per share. From 1x the dividend is covered.

Financial strength 5 of 6 met

  • met: Piotroski F-Score at least 7 of 9 8 of 9
  • not met: Long-term debt no higher than equity 2.32
  • met: Current assets cover current liabilities 1.26
  • met: Positive equity 18.5B USD
  • met: In 5 years, share count up by at most 5% −9.7%
  • met: Free cash flow positive in the last fiscal year 12.8B USD
Piotroski F-Score

8 of 9 Fiscal year 2025

Rank 90 of 100: higher than 90% of 134 peers (All). strong.

Rank 92 of 100: higher than 92% of 19 peers (Sector). strong.

Median Health Care: 7.0 of 9

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

2.32 at fiscal year end

Rank 8 of 100: lower than 8% of 199 peers (All). weak.

Rank 8 of 100: lower than 8% of 18 peers (Sector). weak.

Median Health Care: 0.72

Long-term financial debt divided by equity.

Liquidity (current ratio)

1.26 at fiscal year end

Rank 42 of 100: higher than 42% of 215 peers (All). medium.

Rank 37 of 100: higher than 37% of 26 peers (Sector). medium.

Median Health Care: 1.56

Current assets divided by current liabilities.

Change in share count

−9.7% in 5 years

Rank 79 of 100: lower than 79% of 199 peers (All). strong.

Rank 81 of 100: lower than 81% of 24 peers (Sector). strong.

Median Health Care: −2.7%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • met: Long-term debt relative to total assets fell
  • met: Liquidity (current assets / current liabilities) rose
  • not met: No additional shares (diluted share count did not rise)
  • met: Gross margin higher than the prior year
  • met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light yellow: Revenue grew over 5 years (+2.5% per year), more slowly than the sector median.
  • Light green: Net margin 14.6%, above the sector median (12.9%).
  • Light red: Debt much higher than usual in the sector.
  • Light red: Profit in 8 of 10 fiscal years.
  • Light yellow: High payout ratio (72% of earnings).

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 19.4B USD · Net income 4.5B USD · Net margin 22.9%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 20.8B USD · Net income 1.0B USD · Net margin 4.8%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 22.6B USD · Net income 4.9B USD · Net margin 21.8%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 26.1B USD · Net income 3.4B USD · Net margin 13.2%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 42.5B USD · Net income −9.0B USD · Net margin −21.2%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 46.4B USD · Net income 7.0B USD · Net margin 15.1%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 46.2B USD · Net income 6.3B USD · Net margin 13.7%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 45.0B USD · Net income 8.0B USD · Net margin 17.8%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 48.3B USD · Net income −8.9B USD · Net margin −18.5%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 48.2B USD · Net income 7.1B USD · Net margin 14.6%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 48.2B USD · Net income 7.1B USD · Net margin 14.6%

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 71.1 USD gross profit and 14.6 USD net income remained.

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue48.2B USD100.0%
Gross profit34.3B USD71.1%
Cost of revenue13.9B USD28.9%
Net income7.1B USD14.6%
Research & development10.0B USD20.6%
Interest expense1.9B USD3.9%
Taxes2.3B USD4.7%
Remaining costs & other13.1B USD27.2%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The net margin rose in 5 years from −21.2% to 14.6%.

Gross marginNet margin
  1. Fiscal year 2016: Gross margin 74.5% · Net margin 22.9%
  2. Fiscal year 2017: Gross margin 70.8% · Net margin 4.8%
  3. Fiscal year 2018: Gross margin 71.0% · Net margin 21.8%
  4. Fiscal year 2019: Gross margin 69.1% · Net margin 13.2%
  5. Fiscal year 2020: Gross margin 72.3% · Net margin −21.2%
  6. Fiscal year 2021: Gross margin 78.6% · Net margin 15.1%
  7. Fiscal year 2022: Gross margin 78.0% · Net margin 13.7%
  8. Fiscal year 2023: Gross margin 76.2% · Net margin 17.8%
  9. Fiscal year 2024: Gross margin 71.1% · Net margin −18.5%
  10. Fiscal year 2025: Gross margin 71.1% · Net margin 14.6%

Returns

Return on equity rose in 5 years from −23.8% to 38.2%.

Return on equityReturn on assets
  1. Fiscal year 2016: Return on equity 27.6% · Return on assets 13.2%
  2. Fiscal year 2017: Return on equity 8.6% · Return on assets 3.0%
  3. Fiscal year 2018: Return on equity 35.1% · Return on assets 14.1%
  4. Fiscal year 2019: Return on equity 6.7% · Return on assets 2.6%
  5. Fiscal year 2020: Return on equity −23.8% · Return on assets −7.6%
  6. Fiscal year 2021: Return on equity 19.5% · Return on assets 6.4%
  7. Fiscal year 2022: Return on equity 20.4% · Return on assets 6.5%
  8. Fiscal year 2023: Return on equity 27.3% · Return on assets 8.4%
  9. Fiscal year 2024: Return on equity −54.8% · Return on assets −9.7%
  10. Fiscal year 2025: Return on equity 38.2% · Return on assets 7.8%

Equity and long-term debt

The equity ratio fell in 5 years from 31.9% to 20.5%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2016: Equity 16.2B USD · Long-term debt 5.7B USD
  2. Fiscal year 2017: Equity 11.7B USD · Long-term debt 7.0B USD
  3. Fiscal year 2018: Equity 14.0B USD · Long-term debt 5.6B USD
  4. Fiscal year 2019: Equity 51.6B USD · Long-term debt 43.4B USD
  5. Fiscal year 2020: Equity 37.8B USD · Long-term debt 48.3B USD
  6. Fiscal year 2021: Equity 35.9B USD · Long-term debt 39.6B USD
  7. Fiscal year 2022: Equity 31.1B USD · Long-term debt 35.1B USD
  8. Fiscal year 2023: Equity 29.4B USD · Long-term debt 36.7B USD
  9. Fiscal year 2024: Equity 16.3B USD · Long-term debt 47.6B USD
  10. Fiscal year 2025: Equity 18.5B USD · Long-term debt 42.9B USD

Liquidity (current ratio)

The current ratio fell in 5 years from 1.58 to 1.26.

Current ratio
  1. Fiscal year 2016: Current ratio 1.55
  2. Fiscal year 2017: Current ratio 1.55
  3. Fiscal year 2018: Current ratio 1.61
  4. Fiscal year 2019: Current ratio 1.60
  5. Fiscal year 2020: Current ratio 1.58
  6. Fiscal year 2021: Current ratio 1.52
  7. Fiscal year 2022: Current ratio 1.25
  8. Fiscal year 2023: Current ratio 1.43
  9. Fiscal year 2024: Current ratio 1.25
  10. Fiscal year 2025: Current ratio 1.26

Cash flow

Free cash flow stayed roughly the same in 5 years (12.8B USD).

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 2.9B USD · Capital expenditure 1.2B USD · Free cash flow 1.6B USD
  2. Fiscal year 2017: Operating cash flow 5.3B USD · Capital expenditure 1.1B USD · Free cash flow 4.2B USD
  3. Fiscal year 2018: Operating cash flow 5.9B USD · Capital expenditure 951.0M USD · Free cash flow 5.0B USD
  4. Fiscal year 2019: Operating cash flow 8.1B USD · Capital expenditure 836.0M USD · Free cash flow 7.2B USD
  5. Fiscal year 2020: Operating cash flow 14.1B USD · Capital expenditure 753.0M USD · Free cash flow 13.3B USD
  6. Fiscal year 2021: Operating cash flow 16.2B USD · Capital expenditure 973.0M USD · Free cash flow 15.2B USD
  7. Fiscal year 2022: Operating cash flow 13.1B USD · Capital expenditure 1.1B USD · Free cash flow 11.9B USD
  8. Fiscal year 2023: Operating cash flow 13.9B USD · Capital expenditure 1.2B USD · Free cash flow 12.7B USD
  9. Fiscal year 2024: Operating cash flow 15.2B USD · Capital expenditure 1.2B USD · Free cash flow 13.9B USD
  10. Fiscal year 2025: Operating cash flow 14.2B USD · Capital expenditure 1.3B USD · Free cash flow 12.8B USD

Share count

The share count fell in 5 years by 9.7% (mostly through share repurchases).

Diluted share count
  1. Fiscal year 2016: Diluted share count 1.7B
  2. Fiscal year 2017: Diluted share count 1.7B
  3. Fiscal year 2018: Diluted share count 1.6B
  4. Fiscal year 2019: Diluted share count 1.7B
  5. Fiscal year 2020: Diluted share count 2.3B
  6. Fiscal year 2021: Diluted share count 2.2B
  7. Fiscal year 2022: Diluted share count 2.1B
  8. Fiscal year 2023: Diluted share count 2.1B
  9. Fiscal year 2024: Diluted share count 2.0B
  10. Fiscal year 2025: Diluted share count 2.0B

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
2.49 USD · Fiscal year 2025
Dividend growth per year
3 y +4.4%5 y +6.2%10 y +5.3%
Years without a cut
at least 10 as far as the data goes
Payout ratio
of earnings 72% of free cash flow 39%
To shareholders (5 years)
43.1B USD 45% through repurchases
Share count over 5 years
−9.7% fewer shares – each share is a larger stake

Dividend per share

The dividend per share rose in 5 years from 1.84 USD to 2.49 USD.

Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.
  1. Fiscal year 2016: Dividend per share 1.53 USD
  2. Fiscal year 2017: Dividend per share 1.57 USD
  3. Fiscal year 2018: Dividend per share 1.61 USD
  4. Fiscal year 2019: Dividend per share 1.68 USD
  5. Fiscal year 2020: Dividend per share 1.84 USD
  6. Fiscal year 2021: Dividend per share 2.01 USD
  7. Fiscal year 2022: Dividend per share 2.19 USD
  8. Fiscal year 2023: Dividend per share 2.31 USD
  9. Fiscal year 2024: Dividend per share 2.42 USD
  10. Fiscal year 2025: Dividend per share 2.49 USD

Payout ratios

The payout ratio rose in 4 years from 64.4% to 72.0%.

Payout ratio (earnings)Payout ratio (free cash flow)
  1. Fiscal year 2016: Payout ratio (earnings) 57.7% · Payout ratio (free cash flow) 155.8%
  2. Fiscal year 2017: Payout ratio (earnings) 257.4% · Payout ratio (free cash flow) 61.1%
  3. Fiscal year 2018: Payout ratio (earnings) 53.5% · Payout ratio (free cash flow) 52.4%
  4. Fiscal year 2019: Payout ratio (earnings) 83.6% · Payout ratio (free cash flow) 37.0%
  5. Fiscal year 2020: Payout ratio (earnings) not available · Payout ratio (free cash flow) 30.6%
  6. Fiscal year 2021: Payout ratio (earnings) 64.4% · Payout ratio (free cash flow) 28.9%
  7. Fiscal year 2022: Payout ratio (earnings) 74.2% · Payout ratio (free cash flow) 38.8%
  8. Fiscal year 2023: Payout ratio (earnings) 59.8% · Payout ratio (free cash flow) 37.5%
  9. Fiscal year 2024: Payout ratio (earnings) not available · Payout ratio (free cash flow) 34.9%
  10. Fiscal year 2025: Payout ratio (earnings) 72.0% · Payout ratio (free cash flow) 39.3%

What goes back to shareholders

Over 5 years, 43.1B USD went back to shareholders, 45% of it through share repurchases. That is 65% of the free cash flow of those years.

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2016: Dividends paid 2.5B USD · Share repurchases 231.0M USD · New shares issued (including employee plans) not available · Free cash flow 1.6B USD
  2. Fiscal year 2017: Dividends paid 2.6B USD · Share repurchases 2.5B USD · New shares issued (including employee plans) not available · Free cash flow 4.2B USD
  3. Fiscal year 2018: Dividends paid 2.6B USD · Share repurchases 320.0M USD · New shares issued (including employee plans) not available · Free cash flow 5.0B USD
  4. Fiscal year 2019: Dividends paid 2.7B USD · Share repurchases 7.3B USD · New shares issued (including employee plans) not available · Free cash flow 7.2B USD
  5. Fiscal year 2020: Dividends paid 4.1B USD · Share repurchases 1.5B USD · New shares issued (including employee plans) not available · Free cash flow 13.3B USD
  6. Fiscal year 2021: Dividends paid 4.4B USD · Share repurchases 6.3B USD · New shares issued (including employee plans) not available · Free cash flow 15.2B USD
  7. Fiscal year 2022: Dividends paid 4.6B USD · Share repurchases 8.0B USD · New shares issued (including employee plans) not available · Free cash flow 11.9B USD
  8. Fiscal year 2023: Dividends paid 4.7B USD · Share repurchases 5.2B USD · New shares issued (including employee plans) not available · Free cash flow 12.7B USD
  9. Fiscal year 2024: Dividends paid 4.9B USD · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 13.9B USD
  10. Fiscal year 2025: Dividends paid 5.0B USD · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 12.8B USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Bristol Myers Squibb next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison BMY, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
LLY Lilly (Eli) 65.2B USD +21.6%83.0%–31.7%77.8%23.6%13.8%7/9
MRK Merck & Co. 65.0B USD +6.3%74.8%–28.1%34.7%38.4%19.0%4/9
PFE Pfizer 62.6B USD +8.5%74.3%–12.4%9.0%41.5%14.5%6/9
ABBV AbbVie 61.2B USD +6.0%70.2%24.6%6.9%–−2.4%29.1%8/9
BMY Bristol Myers Squibb this stock 48.2B USD +2.5%71.1%–14.6%38.2%20.5%26.7%8/9
TMO Thermo Fisher Scientific 44.6B USD +6.7%–17.4%15.0%12.6%48.4%14.1%–
ABT Abbott Laboratories 44.3B USD +5.1%56.4%18.2%14.7%12.5%60.1%16.7%6/9
AMGN Amgen 36.8B USD +7.6%67.2%24.7%21.0%89.1%9.6%22.0%7/9
MDT Medtronic 36.4B USD +3.8%65.0%17.8%13.2%9.7%53.2%14.9%7/9
Median of the sector 26 symbols 44.4B USD +8.5%66.6%18.0%13.9%14.3%38.5%14.9%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Figures of the last fiscal year from SEC annual reports (peers as of Oct 28, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light yellow: below sector

+2.5% per year, last 5 years

Sector Health Care: median +7.8% (60 symbols)

What does this mean? Revenue: over 5 years it grew by 2.5% per year on average, but more slowly than the median company in the sector (+7.8%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light gray: not computable

– per year, last 5 years

Sector Health Care: median +7.5% (46 symbols)

per share: not computable (loss in the first or last year)

What does this mean? There was a loss in the first or last year. An annual growth rate cannot be calculated meaningfully then.

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light green: above sector

14.6% last fiscal year

Sector Health Care: median 12.9% (63 symbols)

What does this mean? Of every 100 USD in revenue, 14.64 USD remained as profit – at least as much as the median company in the sector (12.9%). Five years ago the margin was −21.2%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light red: much higher

1.92 latest balance sheet

Sector Health Care: median 0.66 (49 symbols)

What does this mean? For every 1 USD of equity there is 1.92 USD of financial debt – more than twice as much as the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light yellow: high

72% Dividend / earnings per share

Sector Health Care: median 28% (31 symbols)

What does this mean? Of every 1 USD of earnings per share, 0.72 USD went to shareholders as a dividend. Little buffer remains for weaker years. Median company in the sector: 28%.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light red: 2 loss years

8 of 10 fiscal years with a profit

What does this mean? In 8 of the last 10 fiscal years the bottom line showed a profit. 2 years ended with a loss.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
48.2B USD
Revenue vs. prior year
−0.2%
Net income (FY)
7.1B USD
Net income vs. prior year
–
EPS (FY)
3.46 USD
13F funds with a position
0 of 9
Funds vs. prior quarter
−1
Shares held vs. prior quarter
−100.0%
Fiscal year to Dec 31, 2025 · 10-K filed Feb 11, 2026 · Balance sheet Jun 30, 2026 (filed Jul 30, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). 13F: reporting date Jun 30, 2026, 9 tracked funds have filed (latest Aug 14, 2026), filed with up to 45 days of delay. Stock positions only; comparison with Mar 31, 2026 only across funds that filed for both quarters.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 48.2B7.1B 14.6% 3.46 2.49 72%
2024Dec 31, 2024 48.3B−8.9B −18.5% −4.41 2.42 –
2023Dec 31, 2023 45.0B8.0B 17.8% 3.86 2.31 60%
2022Dec 31, 2022 46.2B6.3B 13.7% 2.95 2.19 74%
2021Dec 31, 2021 46.4B7.0B 15.1% 3.12 2.01 64%
2020Dec 31, 2020 42.5B−9.0B −21.2% −3.99 1.84 –
2019Dec 31, 2019 26.1B3.4B 13.2% 2.01 1.68 84%
2018Dec 31, 2018 22.6B4.9B 21.8% 3.01 1.61 53%
2017Dec 31, 2017 20.8B1.0B 4.8% 0.61 1.57 257%
2016Dec 31, 2016 19.4B4.5B 22.9% 2.65 1.53 58%
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q2/26Jun 30, 2026 13.0B3.3B 25.6% 1.62 0.63 39%
Q1/26Mar 31, 2026 11.5B2.7B 23.3% 1.31 0.63 48%
Q4/25*Dec 31, 2025 12.5B1.1B 8.7% – – –
Q3/25Sep 30, 2025 12.2B2.2B 18.0% 1.08 0.62 57%
Q2/25Jun 30, 2025 12.3B1.3B 10.7% 0.64 0.62 97%
Q1/25Mar 31, 2025 11.2B2.5B 21.9% 1.20 0.62 52%
Q4/24*Dec 31, 2024 12.3B72.0M 0.6% – – –
Q3/24Sep 30, 2024 11.9B1.2B 10.2% 0.60 0.60 100%
Q2/24Jun 30, 2024 12.2B1.7B 13.8% 0.83 0.60 72%
Q1/24Mar 31, 2024 11.9B−11.9B −100.4% −5.89 0.60 –
Q4/23*Dec 31, 2023 11.5B1.8B 15.4% – – –
Q3/23Sep 30, 2023 11.0B1.9B 17.6% 0.93 0.57 61%

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $437.2K2 people −$437.2K
6 months $00 people $437.2K2 people −$437.2K
12 months $00 people $2.3M3 people −$2.3M

Latest transactions

  • Sep 9, 2026 Massacesi Cristian Officer Open-market sale 6,249 shares · $403.5K · SEC
  • Aug 25, 2026 Holzer Phil M Officer Open-market sale 500 shares · $33.8K · SEC
  • Apr 1, 2026 Elkins David V Chief financial officer (CFO) Open-market sale 4,481 shares · $278.0K · SEC
  • Apr 1, 2026 Elkins David V Chief financial officer (CFO) Open-market sale 25,519 shares · $1.6M · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Trend score -15

Price vs. EMA 50-15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+0
Highs and lows-20
Relative strength-15

Volatility and trend strength

ADX 14 (trend strength)17.6
Rel. strength 60 d−7.9%

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

Latest news

Posts

No posts on BMY yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: BMY

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly (buy zones every 4 hours), stocks twice a day, precious metals every 4 hours on trading days, extended universe weekly – not in real time.

Log in Sign up free

↑ ↓ select · Enter open · Esc close